Further studies on non-invasive HER3 imaging, both in pre-clinical and clinical settings, would help to understand the in vivo properties of HER3, enabling a more efficient cancer treatment, not only those targeting HER family members but also chemotherapies through the formation of resistance which involves HER3. This evidence concerns the gene ERBB3 and cancer.